The Protein Interactions Expert



News-Events

Congratulations for your publication !

Evry, France - 02 September

Congratulations to Dr. Yun-Jin Jiang lab for their paper “Newly identified Gon4l/Udu-interacting proteins implicate novel functions” in Scientific Reports. We are very happy to see that the Y2H screens with Gon4l/Udu were useful for their research.

We are looking forward handling new projects with our customers.

If you are interested in finding your favorite protein partners fell free to contact us to know more about our yeast two hybrid services.

Congratulations for your publication !

Evry, France - 01 September

Congratulations to PaolaFrancica and her colleagues for their paper “Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining » in Cell Reports. We are very happy to see that the Y2H screen with ERCC6L2 were useful for their research.

We are looking forward handling new projects with our customers.

If you are interested in finding your favorite protein partners fell free to contact us to know more about our yeast two hybrid services.

Want to increase your nanobody affinity?

Evry, France - 24 August

Good is nice but better is great. You deserve more! If you want to increase the affinity of your nanobody form the lama or a synthetic library for particularly challenging applications. We provide you a unique optimization platform using the yeast to meet your needs.

       

Depending on your antigen we can do:

-          An extracellular optimization using the yeast display by cell sorting,

-          or intracellular optimization or intrabodization using Yeast Two-Hybrid technology

visit our new web page to learn more

Our Covid protein-protein interaction project is financed!

Evry - June 22

Thank you to the Agence Nationale de la Recherche (ANR) for the grant provided for our project “Covid-19 protein-protein interaction mapping” (Cov2PIM). Hybrigenics services will establish the map of protein-protein interaction between the viral proteins and the host but also between the viral proteins themselves. Providing new insights on the biology of the virus and new potential targets for therapy.

Hybrigenics Services current business activity

Evry, France - April 15, 2020

In the context of the COVID19 pandemic we hope that your families and colleagues are well and safe.

We would like to let you know that Hybrigenics Services have continued to operate since the beginning of the containment.

  • Our scientific support team is available to answer your questions about your ongoing or future projects. 
  • Health and safety of our employees is of our highest priority. We are taking the appropriate precautions to ensure stringent workplace health and safety measures. 

Hybrigenics is currently collaborating with Pasteur Institute and CNRS Emerging Virus Unit to develop novel reagents to advance diagnostic tools and therapies for COVID19.

We will continue to communicate our scientific advances in the fight against COVID19 response.

Stay home and take care!

Cordially,

 The Hybrigenics Services’ team

Hybrigenics Services is fully independent from Hybrigenics Pharma

Evry, France - October 16, 2019

Please note that Hybrigenics Services (www.hybrigenics-services.com) and Hybrigenics Pharma (www.hybrigenics.com) have been two financially independent companies since January 2017 despite keeping similar names. Our activities are completely distinct and our operations entirely separate.

Hybrigenics Pharma announced on October 23, 2018 that the clinical development of its only drug candidate was discontinued for lack of efficacy. The winding-up of the company was suspended in January, 2019 when Hybrigenics Pharma received a takeover offer. On October 15, 2019 Hybrigenics Pharma announced its takeover by DMS Group with immediate effect.

None of this affects Hybrigenics Services in any way, nor the research we conduct for our clients and partners. We regret the confusion this might cause.

We thank investigators and companies across the world for their trust and continued interest in our services.

Old news

Back to Top